department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

when

Latest
Archive

by source

All Sources
Sources Page

by activity

Most Active
Biggest Pipelines
Recently Active

hiring

Companies Hiring Now
Big Pharma Roles
All Companies →

Drugs & Pipeline

intelligence

Drugs
Patent Cliff

research

Publications
Topics

window

Next 90 Days
All (incl. Past)

by type

PDUFAs
Approvals
Earnings
Readouts

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Calendar
Drugs
Companies
News

Hubs

Topics
Jobs
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
cal
search

Furosemide · pharmadog

pharmadog
drugs
Furosemide

drug

patient view →

Furosemide Sun

Marketedupdated 2mo ago

by Sun Pharmaceutical Industries Ltd

Approved

community read0 votes

Small molecule drug with a maximum clinical stage of Approval (across all indications), with 6 approved and 28 investigational indications.

indications

investigational

Hypertension

all catalysts(6)

approval · 6

News(0)

no news has mentioned this drug yet

brand

Furosemide

generic

furosemide

MOA

Sodium-(potassium)-chloride cotransporter 2 inhibitor

indication

Hepatic Edema

phase

marketed

FUROSCIX (FUROSEMIDE) — FDA approval

FUROSCIX (FUROSEMIDE) — FDA approval

FUROSCIX (FUROSEMIDE) — FDA approval

LASIX ONYU (FUROSEMIDE) — FDA approval

FUROSCIX (FUROSEMIDE) — FDA approval

FUROSEMIDE — FDA approval

Data sources

openFDA · ClinicalTrials.gov

last refreshed 55m ago

Found something off?

🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that

sign in to leave a comment · permanent archive after 5 minutes

no comments yet — first sniff?

Patent cliff

source: FDA Orange Book

first barrier falls

Apr 3, 2034

~7.7 years out

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (4)

Apr 3, 2034formulationUS 10272064
Apr 3, 2034method-of-use (U-3462)US 11433044
Apr 3, 2034formulationUS 12370168
Apr 3, 2034method-of-use (U-3462)US 9884039

Trials studying Furosemide Sun

—Pharmacokinetics and Safety of Commonly Used Drugs in Lactating Women and Breastfed Infantsrecruitingn=1,600
phase1Comparison of Once Daily 40 mg Torsemide With Twice-daily 40 mg Furosemideterminatedn=20
phase1Study to Compare Bioavailability and Pharmacokinetics of a Novel Furosemide Regimen Administered Subcutaneously Versus the Same Dose (80 mg) Administered Intravenously in Healthy Volunteerscompletedn=16
phase1Pharmacokinetics and Pharmacodynamics of Subcutaneous vs Intravenous Furosemide in Healthy Volunteerscompletedn=21
phase1Modular Clinical Pharmacology Study to Evaluate the Drug-drug Interaction Potential and Relative Bioavailability of Saruparibactive not recruitingn=41
phase1A Clinical Study of the Effect of MK-2828 on Rosuvastatin or Furosemide in Healthy People (MK-2828-005)recruitingn=39
N/AA Study to Compare How Different Medicines (Rosuvastatin, Digoxin, Metformin, and Furosemide) Are Handled by the Body of Healthy People and People With Liver Cirrhosiscompletedn=28
phase1A Study in Healthy Men to Test Whether Zongertinib Influences the Amount of 4 Other Medicines (Dabigatran, Rosuvastatin, Metformin, and Furosemide) in the Bloodcompletedn=32

more trials →